Therefore, future attempts on the use of a pyridine-based FAP-targeted pharmacophore for the design of bispecific PSMA/FAP tracers need to include the optimization of linkers such as incorporating a piperazine-based linker to continue improving FAP-binding affinity and tumor uptake. The gene discussed is FAP; the disease is neoplasm.